DOCSLIB.ORG

Mouse Clptm1l Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Clptm1l Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Clptm1l Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Clptm1l conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Clptm1l gene (NCBI Reference Sequence: NM_146047 ; Ensembl: ENSMUSG00000021610 ) is located on Mouse chromosome 13. 17 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 17 (Transcript: ENSMUST00000022102). Exon 3 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Clptm1l gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-269I17 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a knock-out allele exhibit partial prenatal and neonatal lethality; however, surviving mice are fertile and overtly normal with no significant alterations in the development, maturation and differentiation of B- lymphocytes or production of antibodies by antibody secreting cells. Exon 3 starts from about 16.33% of the coding region. The knockout of Exon 3 will result in frameshift of the gene. The size of intron 2 for 5'-loxP site insertion: 1191 bp, and the size of intron 3 for 3'-loxP site insertion: 1308 bp. The size of effective cKO region: ~690 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 2 3 4 17 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Homology arm Exon of mouse Clptm1l cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7190bp) | A(24.63% 1771) | C(23.06% 1658) | T(26.9% 1934) | G(25.41% 1827) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN -------------------------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr13 + 73602973 73605972 3000 browser details YourSeq 232 9 503 3000 85.6% chr11 + 80869357 80869762 406 browser details YourSeq 229 9 505 3000 83.5% chr3 + 154395364 154395757 394 browser details YourSeq 222 9 505 3000 83.3% chr5 + 44526288 44526693 406 browser details YourSeq 220 9 536 3000 92.4% chr8 + 122135215 122135970 756 browser details YourSeq 215 14 324 3000 91.2% chr4 - 94490198 94490507 310 browser details YourSeq 213 1 509 3000 81.8% chr11 + 103555695 103556101 407 browser details YourSeq 206 9 500 3000 83.9% chr7 - 56271954 56272331 378 browser details YourSeq 205 14 498 3000 83.1% chr15 - 39148264 39148638 375 browser details YourSeq 205 14 506 3000 82.9% chr2 + 161631614 161632020 407 browser details YourSeq 203 9 320 3000 88.8% chr10 + 93005171 93005476 306 browser details YourSeq 200 9 329 3000 89.1% chr9 + 51721512 51721839 328 browser details YourSeq 200 1 324 3000 87.1% chr6 + 119790808 119791136 329 browser details YourSeq 199 23 327 3000 88.1% chr10 + 89368584 89368878 295 browser details YourSeq 198 1 329 3000 87.6% chr18 + 74874669 74875017 349 browser details YourSeq 197 1 506 3000 84.3% chrX + 157867042 157867458 417 browser details YourSeq 195 9 498 3000 80.6% chr2 - 80153668 80154052 385 browser details YourSeq 195 41 505 3000 82.9% chr1 + 139293147 139293519 373 browser details YourSeq 193 9 329 3000 89.2% chr5 - 110220121 110220444 324 browser details YourSeq 193 9 326 3000 88.5% chr1 - 157378473 157378798 326 Note: The 3000 bp section upstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr13 + 73606663 73609662 3000 browser details YourSeq 32 1804 1841 3000 82.9% chr1 - 55205064 55205098 35 browser details YourSeq 31 1813 1849 3000 94.3% chr4 - 132979763 132979806 44 browser details YourSeq 28 1813 1840 3000 100.0% chr1 - 164967023 164967050 28 browser details YourSeq 27 1813 1841 3000 96.6% chr12 - 3448281 3448309 29 browser details YourSeq 27 2827 2868 3000 96.6% chr3 + 155738554 155738597 44 browser details YourSeq 27 1813 1841 3000 96.6% chr10 + 12929661 12929689 29 browser details YourSeq 26 1813 1840 3000 96.5% chr4 - 16285480 16285507 28 browser details YourSeq 26 1813 1840 3000 96.5% chr9 + 117631686 117631713 28 browser details YourSeq 26 1813 1840 3000 96.5% chr3 + 117911596 117911623 28 browser details YourSeq 25 1818 1848 3000 96.3% chr12 + 92462195 92462226 32 browser details YourSeq 24 43 70 3000 85.2% chr5 + 106261386 106261412 27 browser details YourSeq 23 48 74 3000 96.0% chr7 - 64217158 64217186 29 browser details YourSeq 23 1818 1840 3000 100.0% chr16 + 82334659 82334681 23 browser details YourSeq 22 61 82 3000 100.0% chr4 + 35139886 35139907 22 browser details YourSeq 21 1820 1840 3000 100.0% chr7 - 40344656 40344676 21 browser details YourSeq 21 2592 2612 3000 100.0% chr4 - 84333711 84333731 21 browser details YourSeq 21 1813 1833 3000 100.0% chr11 - 98172591 98172611 21 browser details YourSeq 21 1813 1833 3000 100.0% chr6 + 132431506 132431526 21 Note: The 3000 bp section downstream of Exon 3 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Clptm1l CLPTM1-like [ Mus musculus (house mouse) ] Gene ID: 218335, updated on 12-Aug-2019 Gene summary Official Symbol Clptm1l provided by MGI Official Full Name CLPTM1-like provided by MGI Primary source MGI:MGI:2442892 See related Ensembl:ENSMUSG00000021610 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Crr9; C130052I12Rik Expression Ubiquitous expression in genital fat pad adult (RPKM 55.3), ovary adult (RPKM 54.4) and 28 other tissues See more Orthologs human all Genomic context Location: 13; 13 C1 See Clptm1l in Genome Data Viewer Exon count: 17 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 13 NC_000079.6 (73604002..73620639) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 13 NC_000079.5 (73741749..73758053) Chromosome 13 - NC_000079.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 4 transcripts Gene: Clptm1l ENSMUSG00000021610 Description CLPTM1-like [Source:MGI Symbol;Acc:MGI:2442892] Gene Synonyms C130052I12Rik Location Chromosome 13: 73,604,006-73,620,605 forward strand. GRCm38:CM001006.2 About this gene This gene has 4 transcripts (splice variants), 250 orthologues, 1 paralogue, is a member of 1 Ensembl protein family and is associated with 11 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Clptm1l-201 ENSMUST00000022102.8 2340 539aa ENSMUSP00000022102.7 Protein coding CCDS56894 Q8BXA5 TSL:1 GENCODE basic APPRIS P1 Clptm1l-204 ENSMUST00000222343.1 830 No protein - Retained intron - - TSL:2 Clptm1l-202 ENSMUST00000221130.1 736 No protein - Retained intron - - TSL:3 Clptm1l-203 ENSMUST00000221417.1 334 No protein - Retained intron - - TSL:3 36.60 kb Forward strand 73.60Mb 73.61Mb 73.62Mb 73.63Mb Genes (Comprehensive set... Clptm1l-201 >protein coding Tert-206 >nonsense mediated decay Clptm1l-203 >retained introCnlptm1l-202 >retained intron Tert-202 >nonsense mediated decay Clptm1l-204 >retained intron Tert-205 >retained intron Tert-201 >protein coding Contigs AC158359.2 > Regulatory Build 73.60Mb 73.61Mb 73.62Mb 73.63Mb Reverse strand 36.60 kb Regulation Legend CTCF Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding merged Ensembl/Havana Non-Protein Coding processed transcript Page 6 of 7 https://www.alphaknockout.com Transcript: ENSMUST00000022102 16.60 kb Forward strand Clptm1l-201 >protein coding ENSMUSP00000022... Transmembrane heli... Low complexity (Seg) Pfam Cleft lip and palate transmembrane 1 PANTHER Cleft lip and palate transmembrane 1 Cleft lip and palate transmembrane protein 1-like protein All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 60 120 180 240 300 360 420 539 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 7 of 7.
Load more

Recommended publications
  • Download These Multimorbidities (
    Dong et al. Genome Medicine (2021) 13:110 https://doi.org/10.1186/s13073-021-00927-6 RESEARCH Open Access A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank Guiying Dong1,2, Jianfeng Feng1,2,3, Fengzhu Sun4, Jingqi Chen1,2,3* and Xing-Ming Zhao1,2,3* Abstract Background: Multimorbidities greatly increase the global health burdens, but the landscapes of their genetic risks have not been systematically investigated. Methods: We used the hospital inpatient data of 385,335 patients in the UK Biobank to investigate the multimorbid relations among 439 common diseases. Post-GWAS analyses were performed to identify multimorbidity shared genetic risks at the genomic loci, network, as well as overall genetic architecture levels. We conducted network decomposition for the networks of genetically interpretable multimorbidities to detect the hub diseases and the involved molecules and functions in each module. Results: In total, 11,285 multimorbidities among 439 common diseases were identified, and 46% of them were genetically interpretable at the loci, network, or overall genetic architecture levels. Multimorbidities affecting the same and different physiological systems displayed different patterns of the shared genetic components, with the former more likely to share loci-level genetic components while the latter more likely to share network-level genetic components. Moreover, both the loci- and network-level genetic components shared by multimorbidities converged on cell immunity, protein metabolism, and gene silencing. Furthermore, we found that the genetically interpretable multimorbidities tend to form network modules, mediated by hub diseases and featuring physiological categories. Finally, we showcased how hub diseases mediating the multimorbidity modules could help provide useful insights for the genetic contributors of multimorbidities.
    [Show full text]
  • Supplemental Materials 1 SUPPLEMENTAL METHODS CSC
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer Identification of MM immunotherapy targets by MS – Supplemental materials 1 SUPPLEMENTAL METHODS 2 CSC-technology 3 Approximately 100 million cells from each biological replicate (n=3-6) were taken 4 through the CSC-Technology workflow as previously described in detail.(1-3) Cells were 5 washed with PBS and oxidized by treatment with 1 mM sodium meta-periodate (Pierce, 6 Rockford, IL) in PBS pH 7.6 for 15 min at 4°C followed by 2.5 mg/ml biocytin hydrazide 7 (Biotium, Hayward, CA) in PBS pH 6.5 for 1 hour at 4°C. Cells were then collected and 8 homogenized in 10mM Tris pH 7.5, 0.5 mM MgCl2 and the resulting cell lysate was centrifuged 9 at 800 x g for 10 min at 4°C. The supernatant was centrifuged at 210,000 x g for 16 hours at 4°C 10 to collect the membranes. The supernatant was removed and the membrane protein pellet was 11 washed with 25 mM Na2CO3 to disrupt peripheral protein interactions. To the resulting 12 membrane pellet, 300µl 100 mM NH4HCO3, 5 mM Tris(2-carboxyethyl) phosphine (Sigma, St. 13 Louis, MO), and 0.1% (v/v) Rapigest (Waters, Milford, MA) were added and placed on a 14 Thermomixer (750 rpm) to continuously vortex. Proteins were allowed to reduce for 10 min at 15 25°C followed by alklylation with 10 mM iodoacetamide for 30 min.
    [Show full text]
  • Spatial Maps of Prostate Cancer Transcriptomes Reveal an Unexplored Landscape of Heterogeneity
    ARTICLE DOI: 10.1038/s41467-018-04724-5 OPEN Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity Emelie Berglund1, Jonas Maaskola1, Niklas Schultz2, Stefanie Friedrich3, Maja Marklund1, Joseph Bergenstråhle1, Firas Tarish2, Anna Tanoglidi4, Sanja Vickovic 1, Ludvig Larsson1, Fredrik Salmeń1, Christoph Ogris3, Karolina Wallenborg2, Jens Lagergren5, Patrik Ståhl1, Erik Sonnhammer3, Thomas Helleday2 & Joakim Lundeberg 1 1234567890():,; Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today. Here we investigate tissue-wide gene expression heterogeneity throughout a multifocal prostate cancer using the spatial transcriptomics (ST) technology. Utilizing a novel approach for deconvolution, we analyze the transcriptomes of nearly 6750 tissue regions and extract distinct expression profiles for the different tissue components, such as stroma, normal and PIN glands, immune cells and cancer. We distinguish healthy and diseased areas and thereby provide insight into gene expression changes during the progression of prostate cancer. Compared to pathologist annotations, we delineate the extent of cancer foci more accurately, interestingly without link to histological changes. We identify gene expression gradients in stroma adjacent to tumor regions that allow for re-stratification of the tumor micro- environment. The establishment of these profiles is the first step towards an unbiased view of prostate cancer and can serve as a dictionary for future studies. 1 Department of Gene Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Science for Life Laboratory, Tomtebodavägen 23, Solna 17165, Sweden. 2 Department of Oncology-Pathology, Karolinska Institutet (KI), Science for Life Laboratory, Tomtebodavägen 23, Solna 17165, Sweden. 3 Department of Biochemistry and Biophysics, Stockholm University, Science for Life Laboratory, Tomtebodavägen 23, Solna 17165, Sweden.
    [Show full text]
  • Statistical Methods for Integrating Disparate Data Sources
    STATISTICAL METHODS FOR INTEGRATING DISPARATE DATA SOURCES by Prosenjit Kundu A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland April, 2020 Copyright 2020 by Prosenjit Kundu All rights reserved Abstract My thesis is about developing statistical methods by integrating disparate data sources with real data applications, and identifying gene-environment interac- tions (G E) in more extensive studies using existing analytical methods. We × propose a general and novel statistical framework for combining information on multivariate regression parameters across multiple different studies which have varying level of covariate information (Chapter 2). We illustrate the method us- ing real data for developing a breast cancer risk prediction model. We propose a generalized method of moments (GMM) approach for analyzing two-phase studies where we take into account the dependent structure of the datasets across the two-phases (Chapter 3). We illustrate the method using real data on Wilm’s tumor, a common type of kidney cancer in children. We analyze the largest gene by smoking interaction study for pancreatic ductal adenocarcinoma risk conducted to date using existing statistical methods (Chapter 4). Primary Readers Nilanjan Chatterjee (Advisor) Professor Department of Biostatistics & Department of Oncology ii Bloomberg School of Public Health, School of Medicine, The Johns Hop- kins University Alison Patricia Klein Professor Department of Oncology School of Medicine, The Johns Hopkins University Mei-Cheng Wang Professor Department of Biostatistics Bloomberg School of Public Health, The Johns Hopkins University Debashree Ray Assisstant Professor Department of Epidemiology Bloomberg School of Public Health, The Johns Hopkins University Alternate Readers Elizabeth L.
    [Show full text]
  • Winners Sorted by Institute-Center
    FARE2020WINNERS Sorted By Institute Ji Chen Postdoctoral Fellow CC Neuroscience - General Toward a Wearable Pediatric Robotic Knee Exoskeleton for Real World Overground Gait Rehabilitation in Ambulatory Individuals Crouch gait, or excessive knee flexion, is a debilitating gait pathology in children with cerebral palsy (CP). Surgery, bracing and therapy provide only short term correction of crouch and more sustainable solutions remain a significant challenge in children with CP. One major hurdle is achieving the required dosage and intensity of gait training necessary to produce meaningful long term improvements in walking ability. Rather than replace lost or absent function, gait training in CP population aims to improve the participant’s baseline walking pattern by encouraging longer bouts of training and exercise, which is different than in those with paralysis. Wearable robotic exoskeletons, as a potential strategy, can assist individuals with CP to gradually regain knee extension over time and help maintain it for longer periods through intense task-specific gait training. We previously tested our initial prototype which produced significant improvement in knee extension comparable in magnitude to reported results from orthopedic surgery. Children continued to exert voluntary knee extensor muscle when walking with the exoskeleton which indicated the device was assisting but not controlling their gait. These positive initial results motivated us to design second prototype to expand the user population, and to enable its effective use outside of the laboratory environment. The current version has individualized control capability and device portability for home use as it implemented a multi-layered closed loop control system and a microcontroller based data acquisition system.
    [Show full text]
  • WO 2015/108719 Al 23 July 2015 (23.07.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/108719 Al 23 July 2015 (23.07.2015) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07K 16/30 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2015/010219 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 6 January 2015 (06.01 .2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/927,330 14 January 2014 (14.01.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: THE MEDICAL COLLEGE OF WISCON¬ DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, SIN, INC.
    [Show full text]
  • 216141 2 En Bookbackmatter 461..490
    Glossary A2BP1 ataxin 2-binding protein 1 (605104); 16p13 ABAT 4-(gamma)-aminobutyrate transferase (137150); 16p13.3 ABCA5 ATP-binding cassette, subfamily A, member 5 (612503); 17q24.3 ABCD1 ATP-binding cassette, subfamily D, member 1 (300371):Xq28 ABR active BCR-related gene (600365); 17p13.3 ACR acrosin (102480); 22q13.33 ACTB actin, beta (102630); 7p22.1 ADHD attention deficit hyperactivity disorder—three separate conditions ADD, ADHD, HD that manifest as poor focus with or without uncontrolled, inap- propriately busy behavior, diagnosed by observation and quantitative scores from parent and teacher questionnaires ADSL adenylosuccinate lyase (608222); 22q13.1 AGL amylo-1,6-glucosidase (610860); 1p21.2 AGO1 (EIF2C1), AGO3 (EIF2C3) argonaute 1 (EIF2C1, eukaryotic translation initiation factor 2C, subunit 1 (606228); 1p34.3, argonaute 3 (factor 2C, subunit 3—607355):1p34.3 AKAP8, AKAP8L A-kinase anchor protein (604692); 19p13.12, A-kinase anchor protein 8-like (609475); 19p13.12 ALG6 S. cerevisiae homologue of, mutations cause congenital disorder of glyco- sylation (604566); 1p31.3 Alopecia absence of hair ALX4 aristaless-like 4, mouse homolog of (605420); 11p11.2 As elsewhere in this book, 6-digit numbers in parentheses direct the reader to gene or disease descriptions in the Online Mendelian Disease in Man database (www.omim.org) © Springer Nature Singapore Pte Ltd. 2017 461 H.E. Wyandt et al., Human Chromosome Variation: Heteromorphism, Polymorphism and Pathogenesis, DOI 10.1007/978-981-10-3035-2 462 Glossary GRIA1 glutamate receptor,
    [Show full text]
  • The TERT-CLPTM1L Locus for Lung Cancer Predisposes to Bronchial Obstruction and Emphysema
    Eur Respir J 2011; 38: 924–931 DOI: 10.1183/09031936.00187110 CopyrightßERS 2011 The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema E. Wauters*,#,",e, D. Smeets*,#,e, J. Coolen+, J. Verschakelen+, P. De Leyn1, M. Decramer", J. Vansteenkiste", W. Janssens" and D. Lambrechts*,# ABSTRACT: Clinical studies suggest that bronchial obstruction and emphysema increase AFFILIATIONS susceptibility to lung cancer. We assessed the possibility of a common genetic origin and *Vesalius Research Center (VRC), VIB, investigated whether the lung cancer susceptibility locus on chromosome 5p15.33 increases the #VRC, KU Leuven, and, risk for bronchial obstruction and emphysema. "Respiratory Division, and, Three variants in the 5p15.33 locus encompassing the TERT and CLPTM1L genes were Depts of +Radiology, and, 1 genotyped in 777 heavy smokers and 212 lung cancer patients. Participants underwent pulmonary Thoracic Surgery, University Hospital Gasthuisberg, KU Leuven, function tests and computed tomography of the chest, and completed questionnaires assessing Leuven, Belgium. smoking behaviour. eThese authors contributed equally to The rs31489 C-allele correlated with reduced forced expiratory volume in 1 s (p50.006). this work. Homozygous carriers of the rs31489 C-allele exhibited increased susceptibility to bronchial CORRESPONDENCE 5 obstruction (OR 1.82, 95% CI 1.24–2.69; p 0.002). A similar association was observed for D. Lambrechts diffusing capacity of the lung for carbon monoxide (p50.004). Consistent with this, CC-carriers Vesalius Research Center, VIB had an increased risk of emphysema (OR 2.04, 95% CI 1.41–2.94; p51.73610-4) and displayed KU Leuven greater alveolar destruction.
    [Show full text]
  • CIHR STAGE Program Advisory Committee Meeting January 24 & 25, 2013 Toronto, Ontario PROGRESS REPORT RECRUITMENT and BUDGET
    2012 ANNUAL REPORT CIHR STAGE Program Advisory Committee Meeting January 24 & 25, 2013 Toronto, Ontario PROGRESS REPORT RECRUITMENT AND BUDGET Page Page 01 01 Co-Directors Message 1 STAGE Competitions: Applicant-Publication 20 02 Records-Comparison Co-principal Investigators, Co-investigators, 3 02 and Collaborators Projected and Actual Admissions 22 03 03 Summary of Changes 5 Current Trainees 23 04 04 Progress 8 Alumni 25 05 05 List of Acronyms 17 Trainee Productivity 26 06 06 Governance Structure 18 Trainee Awards, Distinctions, and Honours 27 07 Budget 29 CURRICULUM APPENDICES Page A Summary of Grant Proposal 01 Components, Training Objectives, and 30 B List of Trainee Publications Assessable Outcomes C Representative Trainee Publications 02 Integrative and Cross-disciplinary Courses 32 D List of Mentors 03 International Speaker Seminar Series 34 E Mentors-Mentee Agreement F Syllabi-Integrative Courses G Steering Committee Meeting Minutes, Oct. 2012 H STAGE International Internship and Travel Award Programs I Syllabi and Agendas for Professional Development Courses and Workshops J Trainee Annual Progress Report and Exit Survey K GAW18 Workshop - Resulting Papers and Participating STAGE Mentors and Trainees L Mentoring Commitment Message STAGE - PAC 2012 Annual Report Page 5 01 CO-DIRECTORS MESSAGE Drs. SHELLEY B. BULL & FRANCE GAGNON Dear members of the Program Advisory Committee: Thank you very much for your wise counsel and valuable guidance regarding the progress of STAGE and its future directions. Your critical evaluation of how STAGE fulfils its mission and objectives, and how it can improve is essential. The program’s midterm review by the Canadian Institutes for Health Research (CIHR) (Strategic Training Initiative in Health Research (STIHR) Program) on November 2013 will determine funding for the last three years of operation, until 2016.
    [Show full text]
  • Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer
    ORIGINAL ARTICLE Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer Yanhong Liu, PhD,a Farrah Kheradmand, MD,a Caleb F. Davis, PhD,a Michael E. Scheurer, PhD,a David Wheeler, PhD,a Spiridon Tsavachidis, MS,a Georgina Armstrong, MPH,a Claire Simpson, PhD,b Diptasri Mandal, PhD,c Elena Kupert, MS,d Marshall Anderson, PhD,e Ming You, MD, PhD,e Donghai Xiong, PhD,e Claudio Pikielny, PhD,f Ann G. Schwartz, PhD,g Joan Bailey-Wilson, PhD,h Colette Gaba, MPH,i Mariza De Andrade, PhD,j Ping Yang, MD, PhD,j Susan M. Pinney, PhD,d The Genetic Epidemiology of Lung Cancer Consortium, Christopher I. Amos, PhD,f Margaret R. Spitz, MDa,* aBaylor College of Medicine, Houston, TX, USA bNational Institutes of Health, Baltimore, MD, USA cLouisiana State University Health Sciences Center, New Orleans, LA, USA dUniversity of Cincinnati College of Medicine, Cincinnati, OH, USA eMedical College of Wisconsin, Milwaukee, WI, USA fDartmouth College, Lebanon, NH, USA gKarmanos Cancer Institute, Wayne State University, Detroit, MI, USA hHuman Genome Research Institute, Bethesda, MD, USA iThe University of Toledo College of Medicine, Toledo, OH, USA jMayo Clinic College of Medicine, Rochester, MN, USA Received 21 July 2015; revised 21 September 2015; accepted 25 September 2015 ABSTRACT dopamine b-hydroxylase (DBH) gene at 9q34.2 was identified in two sporadic cases; the minor allele frequency of this mutation Introduction: The association between smoking-induced is 0.0034 according to the 1000 Genomes database. We chronic obstructive pulmonary disease (COPD) and lung cancer also observed three suggestive rare mutations on 15q25.1: (LC) is well documented.
    [Show full text]
  • Platform Abstracts
    The 12th International Congress of Human Genetics and the American Society of Human Genetics 61st Annual Meeting October 11-15, 2011 Montreal, Canada PLATFORM ABSTRACTS Abstract/ Abstract/ Program Program Numbers Numbers Plenary Session Concurrent Platform Session C (51-60) Wednesday, October 12, 8:00 am – 10:00 am Friday, October 14, 4:15 pm – 6:15 pm SESSION 3 – Plenary Session on Epigenetics 1-2 SESSION 51 – Cancer Genetics II: Ovarian and Breast 163-170 These two abstracts were selected by the Scientific Program SESSION 52 – Genomics III: Genome Expression 171-178 Committee to be included in this invited plenary session with Douglas SESSION 53 – Molecular Basis III: Ciliopathies 179-186 Wallace and Emma Whitelaw. SESSION 54 – Statistical Genetics III: Analysis of 187-194 Sequence Data Concurrent Platform Sessions A (10-19) SESSION 55 – Epigenetics 195-202 Wednesday, October 12, 4:15 pm – 6:15 pm SESSION 56 – Complex Traits I: Approaches and Methods 203-210 SESSION 10 – Population Genetics 3-10 SESSION 57 – Cardiovascular Genetics II: Single Gene and 211-218 SESSION 11 – Genomics I: Structural Variation 11-18 Chromosomal Conditions SESSION 12 – Neurogenetics I: Autism 19-26 SESSION 58 – Neurogenetics III: Alzheimer, Parkinson and 219-226 SESSION 13 – Clinical Genetics I: Genotype-Phenotype 27-34 Neurodegenerative Diseases Correlation in Syndromes SESSION 59 – Clinical Genetics II: Neurodevelopmental 227-234 SESSION 14 – Chromosome Organization and Cancer 35-42 Disorders Cytogenetics SESSION 60 – Ethical, Legal, Social and Policy Issues
    [Show full text]
  • The TERT-CLPTM1L Locus for Lung Cancer Predisposes to Bronchial Obstruction and Emphysema
    ERJ Express. Published on May 26, 2011 as doi: 10.1183/09031936.00187110 The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema 1,2,3* 1,2* 4 4 Els Wauters , Dominiek Smeets , Johan Coolen , Johny Verschakelen , Paul De Leyn5, Marc Decramer3, Johan Vansteenkiste3, Wim Janssens3, Diether Lambrechts1,2 1. Vesalius Research Center (VRC), VIB, 3000 Leuven, Belgium. 2. Vesalius Research Center (VRC), K.U.Leuven, 3000 Leuven, Belgium. 3. Respiratory Division, University Hospital Gasthuisberg, K.U.Leuven, Belgium. 4. Department of Radiology, University Hospital Gasthuisberg, K.U.Leuven, Belgium. 5. Department of Thoracic surgery, University Hospital Gasthuisberg, K.U.Leuven, Belgium. * These authors contributed equally to this work Corresponding author: Diether Lambrechts, MSc, PhD. Vesalius Research Center VIB, KULeuven Campus Gasthuisberg, Herestraat 49, box 912 B-3000, Leuven, Belgium Tel: +32-16-34.61.31; Fax: +32-16-34.59.90 E-mail: [email protected] Funding: E.W. is supported by the Vlaamse Liga tegen Kanker (VLK), W.J. by the Fund for Scientific Research Flanders (FWO). Keywords: chronic obstructive pulmonary disease, emphysema, lung cancer, susceptibility, telomerase reverse transcriptase gene Running title: The 5p15.33 locus in bronchial obstruction and emphysema Copyright 2011 by the European Respiratory Society. ABSTRACT Clinical studies suggest that bronchial obstruction and emphysema increase susceptibility to lung cancer. We assess the possibility of a common genetic origin and investigate whether the lung cancer susceptibility locus on chromosome 5p15.33 increases the risk for bronchial obstruction and emphysema. Three variants in the 5p15.33 locus encompassing the TERT and CLPTM1L genes were genotyped in 777 heavy smokers and 212 lung cancer patients.
    [Show full text]